Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Gordon

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
JCI Insight|December 27, 2016
Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severityShane Lofgren, Monique Hinchcliff, Mary Carns, et al.
Cell Reports|August 1, 2023
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunityAlexander Muik, Bonny Gaby Lui, Jasmin Quandt, et al.
Arthritis Research & Therapy|June 15, 2021
Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohortSara Jaafar, Alain Lescoat, Suiyuan Huang, et al.
Arthritis Care & Research|April 25, 2024
Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic SclerosisBoyang Zheng, Mianbo Wang, Kerry McKenna, et al.
Annals of the Rheumatic Diseases|July 17, 2024
Racial variability in immune responses only partially explains differential systemic sclerosis disease severityKamini E Kuchinad, Ji Soo Kim, Adrianne Woods, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
JMIR Research Protocols|April 25, 2020
The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility TrialMarie-Eve Carrier, Linda Kwakkenbos, Warren R Nielson, et al.
Pilot and Feasibility Studies|February 27, 2022
Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) ProgramLinda Kwakkenbos, Nora Østbø, Marie-Eve Carrier, et al.
Rheumatology (Oxford, England)|June 6, 2018
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohortsDane H Dougherty, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Trials|November 28, 2021
The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trialJulia Nordlund, Richard S Henry, Linda Kwakkenbos, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
JCI Insight|December 27, 2016
Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severityShane Lofgren, Monique Hinchcliff, Mary Carns, et al.
Cell Reports|August 1, 2023
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunityAlexander Muik, Bonny Gaby Lui, Jasmin Quandt, et al.
Arthritis Research & Therapy|June 15, 2021
Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohortSara Jaafar, Alain Lescoat, Suiyuan Huang, et al.
Arthritis Care & Research|April 25, 2024
Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic SclerosisBoyang Zheng, Mianbo Wang, Kerry McKenna, et al.
Annals of the Rheumatic Diseases|July 17, 2024
Racial variability in immune responses only partially explains differential systemic sclerosis disease severityKamini E Kuchinad, Ji Soo Kim, Adrianne Woods, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
JMIR Research Protocols|April 25, 2020
The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility TrialMarie-Eve Carrier, Linda Kwakkenbos, Warren R Nielson, et al.
Pilot and Feasibility Studies|February 27, 2022
Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) ProgramLinda Kwakkenbos, Nora Østbø, Marie-Eve Carrier, et al.
Rheumatology (Oxford, England)|June 6, 2018
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohortsDane H Dougherty, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Trials|November 28, 2021
The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trialJulia Nordlund, Richard S Henry, Linda Kwakkenbos, et al.
Pageof 4